KAIST Study Quantifies the Science Cost of Unilateral Dual-Use Research Oversight

A peer-reviewed study published in Science on June 5, 2026 puts numbers to a tension that biosecurity analysts have argued about for years: tightening domestic oversight of dual-use research may hurt the country doing the tightening more than it stops the research from happening elsewhere.

The paper, "Dual-use research under scrutiny" (DOI: 10.1126/science.aee2479), is the first large-scale empirical treatment of the problem. <cite index="21-2">An analysis of approximately 600,000 research papers reveals structural limits to single-country security oversight of dual-use research and identifies trade-offs that policymakers face when strengthening such oversight.</cite> The author, Professor Seokbeom Kwon of KAIST's School of Business and Technology Management, worked as a sole author, combining patent and publication citation data to build his analytical framework.

<cite index="23-10">Kwon developed a new analytical methodology combining the U.S. Patent and Trademark Office's multi-stage security review process with patent-paper citation data.</cite> That pairing matters: patent secrecy orders are one of the few levers the U.S. government has to suppress the publication of research flagged as a national security concern, so the USPTO pipeline offers a rare empirical window into how oversight actually flows.

The policy hook is direct. <cite index="20-6,20-7">The United States has been strengthening security oversight of dual-use research, and most recently, Executive Order 14292, signed in May 2025, intensified federal oversight of biological research with potential security implications, including dangerous gain-of-function research.</cite> But Kwon's findings complicate the logic behind unilateral action. <cite index="22-5">Kwon articulates that unilateral imposition of rigorous oversight by a single nation may yield disproportionate detriments to its own scientific community without effectively curbing analogous research trajectories overseas.</cite>

That structural argument has a legal hook already embedded in existing U.S. policy. <cite index="23-8,23-9">U.S. ex-ante security oversight institutions are based on National Security Decision Directive 189 (NSDD-189) and apply when the federal government is involved in research, meaning that research conducted without federal government involvement effectively falls outside the jurisdiction of this oversight.</cite> In plain terms: the jurisdiction is narrower than the threat landscape.

The dual-use ambiguity the paper is probing is real and not easily resolved. <cite index="19-4,19-5">Dual-use research has both legitimate civilian applications, such as vaccine and treatment development, and potential security-sensitive applications, such as biological weapons or bioterrorism, with examples including research on viral transmission mechanisms or pathogen behavior.</cite> Neither the research community nor regulators have a clean bright line for where one ends and the other begins, and Kwon's data does not manufacture one. The paper instead maps the cost side of the oversight ledger, which is the half that policymakers routinely undercount.

Kwon's own summary, as reported in the KAIST press release reviewed by Mirage News, is that <cite index="21-6">"strengthening security oversight on dual-use research by a single country alone may impose disproportionate costs on domestic science, while having structural limits in preventing the development of equally important research conducted overseas,"</cite> and that international cooperation and balanced policy design could help mitigate these tensions.

<cite index="22-8">The implications extend beyond biological sciences, as Kwon's study anticipates similar challenges in emerging high-stakes fields such as artificial intelligence and quantum technologies.</cite> That framing is worth noting but should be held at moderate confidence; the empirical base of the paper is biological and chemistry-adjacent research, and the extension to AI and quantum is the author's extrapolation, not a finding.

The timing is consequential regardless. The Trump administration's fiscal year 2026 budget proposed steep cuts across the federal biosecurity apparatus. <cite index="4-1">Budget recommendations to Congress proposed cuts including a reduction of $18 billion to the National Institutes of Health, $3.6 billion to the Centers for Disease Control and Prevention, and $240 million to the Administration for Strategic Preparedness and Response.</cite> <cite index="4-2">The cuts would coincide with increasingly dwindling staff across key federal biosecurity-related agencies and a leaderless White House Office of Pandemic Preparedness and Response Policy following the recent resignation of top official Gerald Parker.</cite>

Kwon's paper doesn't argue for less oversight. It argues for oversight designed with the international research ecosystem in mind, not just the domestic one. That's a harder policy problem than writing an executive order, and the data now suggest it's the right one to solve.

Sources cited:
- Science (via KAIST / Mirage News) (https://www.miragenews.com/kaist-analyzes-dual-use-research-security-1687035/)
- EurekAlert / KAIST press release (https://www.eurekalert.org/news-releases/1131017)
- Homeland Security Newswire (https://www.homelandsecuritynewswire.com/dr20260608-first-largescale-empirical-analysis-of-dualuse-research-and-security-oversight)
- CSIS (Opportunities to Strengthen U.S. Biosecurity from AI-Enabled Bioterrorism) (https://www.csis.org/analysis/opportunities-strengthen-us-biosecurity-ai-enabled-bioterrorism-what-policymakers-should)